Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leah Z Rand

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
JAMA|June 8, 2023
Congress' Misguided Plan to Ban QALYsLeah Z Rand, Adam Raymakers, Benjamin N Rome
AMA Journal of Ethics|November 7, 2022
What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?Sarosh Nagar, Leah Z Rand, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 7, 2026
Conflicts of Interest in FDA Advisory Committees: A Systematic Literature ReviewArianna Gentilini, Adam J N Raymakers, Leah Z Rand
The American Journal of Bioethics : AJOB|July 30, 2025
The Limits of Physician-Level Interventions for Cost-Related Nonadherence: A Case for Structural ReformDaniel Eisenkraft Klein, Aaron S Kesselheim, Leah Z Rand
Health Services Research|December 20, 2022
Alternatives to the quality-adjusted life year: How well do they address common criticisms?Leah Z Rand, G J Melendez-Torres, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 4, 2024
The Value of the Quality-Adjusted Life YearsRichard J Willke, Laura T Pizzi, Leah Z Rand, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 27, 2022
High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular MedicineFrazer A Tessema, Ameet Sarpatwari, Leah Z Rand, et al.
Journal of Cancer Policy|February 2, 2025
An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncologyAdam J N Raymakers, Leah Z Rand, William B Feldman, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 6, 2025
Impostor Syndrome: Fraudulent Participants in Qualitative Research Can Skew ResultsLeah Z Rand, Sarah McGraw, Junyi Wang, et al.
Health Affairs (Project Hope)|August 4, 2025
Health Technology Assessment, Again: A Transparent, Evidence-Based Approach For CMS Drug Price NegotiationsDaniel A Ollendorf, Leah Z Rand, Alessandra Blonda, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
JAMA|June 8, 2023
Congress' Misguided Plan to Ban QALYsLeah Z Rand, Adam Raymakers, Benjamin N Rome
AMA Journal of Ethics|November 7, 2022
What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?Sarosh Nagar, Leah Z Rand, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 7, 2026
Conflicts of Interest in FDA Advisory Committees: A Systematic Literature ReviewArianna Gentilini, Adam J N Raymakers, Leah Z Rand
The American Journal of Bioethics : AJOB|July 30, 2025
The Limits of Physician-Level Interventions for Cost-Related Nonadherence: A Case for Structural ReformDaniel Eisenkraft Klein, Aaron S Kesselheim, Leah Z Rand
Health Services Research|December 20, 2022
Alternatives to the quality-adjusted life year: How well do they address common criticisms?Leah Z Rand, G J Melendez-Torres, Aaron S Kesselheim
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 4, 2024
The Value of the Quality-Adjusted Life YearsRichard J Willke, Laura T Pizzi, Leah Z Rand, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 27, 2022
High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular MedicineFrazer A Tessema, Ameet Sarpatwari, Leah Z Rand, et al.
Journal of Cancer Policy|February 2, 2025
An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncologyAdam J N Raymakers, Leah Z Rand, William B Feldman, et al.
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 6, 2025
Impostor Syndrome: Fraudulent Participants in Qualitative Research Can Skew ResultsLeah Z Rand, Sarah McGraw, Junyi Wang, et al.
Health Affairs (Project Hope)|August 4, 2025
Health Technology Assessment, Again: A Transparent, Evidence-Based Approach For CMS Drug Price NegotiationsDaniel A Ollendorf, Leah Z Rand, Alessandra Blonda, et al.
Pageof 3